Background. Information on the performance of anal cytology in women who are high risk for human papillomavirus-related lesions and the factors that might influence cytology are largely lacking.
Women with a previous history of human papillomavirus (HPV)-related lower genital tract high-grade squamous intraepithelial lesions (HSIL) or cancer are a high-risk group for anal cancer [1] [2] [3] . A 13-fold increase in risk has been described, with a higher risk in those with previous vulvar lesions [3] . It has been reported that women diagnosed with anal cancer are 10 times more likely to have a history of HPV-related gynecological cancer compared with matched controls. Several studies have also found a higher risk of anal squamous intraepithelial lesions (ASIL)/anal intraepithelial neoplasia (AIN) in patients with lower genital tract neoplasia (LGTN) [4] [5] [6] .
A reduction in cervical cancer rates and mortality has been achieved through cervical cancer screening based on cervical cytology [7] . Following the parallels recognized between anal and cervical carcinogenesis, a similar strategy based on cytology, with referral of those with abnormalities to high-resolution anoscopy (HRA), has been advocated (by some) for high-risk groups [8] . In high-risk women (eg, human immunodeficiency virus [HIV] positive), anal cytology screening has been recommended by the Infectious Diseases Society of America [9] and is routinely performed in some institutions [10] .
Most studies that have evaluated the performance of anal cytology in comparison to HRA and histology were performed in HIV-positive men and/or men-who-have sex with men (MSM) [11] [12] [13] [14] [15] [16] , with few that exclusively focus on high-risk women. This is a less well-studied group, and information on the sensitivity and specificity of anal cytology relative to HRA and histology is scant. In addition to the limited number of published studies, in most cases with small samples of cytology/histology for comparison and low rates of abnormal results, there is also significant variation in the reported sensitivity for detecting histological abnormalities, ranging from 8% [17] to 70% [18] . There is a need for data from larger patient cohorts and for evaluation of the correlation between cytology and HRA/histology in different settings and in relation to patient and lesion characteristics. This information is required to identify the optimal screening strategy for any given population.
METHODS

Study Design and Inclusion and Exclusion Criteria
This was a retrospective study including all new referrals of women with a previous history of anogenital neoplasia to the Homerton Anal Neoplasia Service (HANS) from January 2012 to July 2017. Although, this was a retrospective analysis, patient information was available from prospectively collected data, filled out at the time of the patient consultation. HANS is a tertiary reference center in London that is dedicated to anal neoplasia diagnosis and treatment. Inclusion criteria were women with a previous history of anogenital neoplasia of low grade (including condyloma), high grade, or cancer; anal cytology and HRA with or without biopsies performed at the same sitting; and new referral between January 2012 and July 2017. Paucicellular cytological samples and incomplete/unsatisfactory HRA were excluded. The Health Research Authority approved this research.
Outcomes
Our primary outcome was to evaluate the sensitivity, specificity, and positive and negative predictive values (PPV and NPV) of "any abnormality" on anal cytology (all abnormal results, excluding any negative cytology) to predict findings on HRA and histology in women with a history of lower anogenital tract neoplasia. As described in a previous study by our group [16] , for comparison with histology, the following 2 outcomes were considered: the presence of any histological abnormality (low grade, high grade, or cancer) and the presence of HSIL/cancer.
Our secondary outcomes were to evaluate factors that can influence the performance of anal cytology in this population and the concordance between anal cytology and histological grades.
Anal Cytology
Anal cytology was always performed before HRA using a sterile flocked swab (MWE, Corsham, United Kingdom), with patients in the lithotomy position. The swab was introduced blindly into the anal canal and gradually withdrawn with rotational movement and the application of gentle pressure for 30 seconds. Samples were placed into PreservCyt ThinPrep solution (Hologic UK, Crawley, United Kingdom) and stirred for 20 seconds. Experienced operators all trained by M. N. collected the samples.
Anal cytology was read by a limited number of experienced cytopathologists, all practicing at the same institution. Classification of cytology was carried out according to the guidelines for reporting cervical cytopathology in the United Kingdom. The most recent National Health Service Cervical Screening Program recommendations (3rd ed.) were published in 2013 [19] . This study enrolled patients starting in 2012, so the previous classification was also used. The reports of anal cytology (based on cervical cytology) included negative, borderline changes, borderline changes with koilocytosis, mild/lowgrade dyskaryosis, moderate dyskaryosis, severe dyskaryosis, and possible invasive squamous invasive carcinoma. Moderate and severe dyskaryosis were considered together as high-grade cytology, whereas all other categories, except negative cytology and invasive, were included in the low-grade category. Four possible cytological categories were therefore used in this study: negative, low grade, high grade, and squamous cell carcinoma.
High-Resolution Anoscopy and Histology
HRA was performed using an Olympus colposcope (Tokyo, Japan). Patients were observed in the lithotomy position with a disposable anoscope inserted and a colposcope used to examine the squamocolumnar junction, the anal canal, and the perianus after the topical application of 5% acetic acid. Biopsies were obtained using a Tischler punch-biopsy forceps in areas of suspicion for HSIL and/or cancer. After the examination, a diagrammatic representation of the areas of disease was drawn, with reference to the location, the number of quadrants involved, and the diagnostic impression of a normal examination, LSIL, HSIL, and/or cancer. Anal and perianal HSIL circumferential extension was described using 4 possible categories: ≤25% (1 quadrant), >25% and ≤50% (2 quadrants), >50% and ≤75% (3 quadrants), and >75% (4 quadrants).
For this study the lower anogenital squamous terminology (LAST), including the terms "low-grade squamous intraepithelial lesions" (LSIL) and "high-grade squamous intraepithelial lesions" (HSIL), was routinely used [20] . p16 positive AIN2 lesions were considered HSIL and AIN2 p16 negative lesions as LSIL. The presence of a cytopathic effect of anal HPV (koilocytosis) and condyloma were considered LSIL as defined with LAST. Four possible histological grades were used in this analysis: normal/negative, LSIL, HSIL, and squamous cell carcinoma. Several experienced pathologists, all from the same institution, read the anal histology slides, with consensus discussion of all difficult or equivocal cases. When several biopsies with different levels of abnormality were taken from the same patient, the most severe histological grade was used for the analysis.
Statistical Analysis
Sensitivity, specificity, NPV, and PPV were calculated with associated 95% confidence intervals (CIs). In most of the analyses presented, repeat observations were included for some patients. Consequently, estimates of diagnostic indices were adjusted for within-patient clustering using generalized estimating equations (GEEs) logistic regression [21, 22] , with an "exchangeable" correlation structure for each individual and robust variance estimation for the parameters. Differences in sensitivity according to factors of interest were also evaluated within the GEE logistic regression framework.
Multivariable GEE logistic regression including all potential predictive variables was also conducted for the outcome of "any abnormality" on anal cytology without considering the histology results (ie, to identify variables associated with the presence of abnormal cytology unrelated to its sensitivity for predicting histology). Backward stepwise variable selection was implemented using factors that were significant on univariable analysis.
The concordance between cytological grades and histological grades was assessed using the Cohen kappa coefficient (κ). There was only a small number of cases with missing data for the variables potentially associated with the sensitivity of anal cytology, so complete case analyses were conducted.
Statistical analysis was performed using Stata, version 14.1 (StataCorp, College Station, Texas).
RESULTS
During the study period, there were 334 new referrals, of which 279 women had a previous history of anogenital neoplasia and concomitant anal cytology and HRA performed. This corresponded to 670 appointments with anal cytology and satisfactory HRA in the same sitting, but 34 anal cytology samples were paucicellular (5%) and were excluded. The final analysis included 278 women from whom 636 anal cytological samples (with the same number of matching HRA) and 323 biopsies were obtained.
The mean age of the women included (age at first visit) was 46 ± 15 years, 34 patients (12%) were HIV positive, 38 patients (14%) were on chronic immunomodulators/immunosuppressive medications, and 137 of 250 (55%), from whom data were available, were current or previous smokers. A history of anogenital HSIL or cancer was present in 199/270 (74%) women, with the following breakdown of affected sites: 94/268 (35%) cervical, 94/270 (35%) vulvar, 14/270 vaginal (5%), 65/270 (24%) anal, and 31/270 (11%) perianal. In some cases (missing cases) a clear distinction between a previous history of low and high grade was not recorded.
A total of 205 (32%) anal cytology samples and 356 HRA (56%) were described as having abnormal results (any abnormality). From the 323 biopsies collected, 260 (80%) were diagnosed as having ASIL (any abnormality), with 105 (33%) biopsies classified as HSIL/cancer.
Overall sensitivity of "any abnormality" on anal cytology to predict any abnormality in HRA was 44% (95% CI, 38%-50%) and specificity was 85% (95% CI, 79%-89%). Overall sensitivity of "any abnormality" on anal cytology to predict any abnormality in histology was 47% (95% CI, 41%-54%) and specificity was 84% (95% CI, 73%-91%). Overall sensitivity of "any abnormality" on anal cytology to predict HSIL or cancer in histology was 71% (95% CI, 61%-79%), with a specificity of 73% (95% CI, 66%-79%; Table 1 ). There was a poor concordance between anal cytological grades and histological grades (κ = 0.147; Table 2 ).
Immunosuppression due to HIV or chronic immunomodulators/immunosuppressive medications was associated with a higher sensitivity of anal cytology to predict any abnormality in histology (63% vs 40%, P = .002) and also for HSIL/cancer (92% vs 60%, P = .002). In those immunosuppressed, the NPV of a negative anal cytology for the absence of HSIL/cancer was 93% (95% CI, 79%-98%; Table 3 ).
Considering the outcome of "any HSIL on histology, " the sensitivity of "any abnormality" on anal cytology to detect HSIL was higher when 2 or more quadrants were affected compared with only 1 quadrant (86% vs 57%; P = .006). No further improvement was seen when HSIL was present in 3 or more (sensitivity 83%, P = .896) or 4 quadrants (sensitivity 82%, P = .828). A significant positive association remained between immunosuppressed status (OR, 5.62; 95% CI, 1.50-21.1; P = .01) and the sensitivity of "any abnormality on anal cytology" to detect HSIL, following adjustment for the presence of HSIL in 2 or more quadrants.
The presence of a previous vulvar HSIL or cancer was associated with higher sensitivity of "any abnormality" on anal cytology to predict any abnormality on histology (57% vs 41%, P = .028; Table 4 ), but a significant difference was not found in the sensitivity for HSIL or cancer on histology (74% vs 67%, P = .469). Patients with a concomitant histologically proven genital HSIL/ cancer (in the same sitting as anal cytology) had a higher sensitivity of anal cytology to predict any abnormality in anal histology than those without (80% vs 42%, P < .001). The difference in sensitivity to predict HSIL/cancer between the 2 groups was not Overall n/n values are shown but do not correspond exactly to point estimates of indices owing to statistical correction for repeat observations. statistically significant (P = .053), although it was higher in those with concomitant genital HSIL/cancer (88% vs 66%; Table 5 ). No significant difference in the sensitivity for either any abnormality in histology or HSIL/cancer on histology, respectively, was observed for patients aged ≥50 years (P = .615, P = .275), smoking history (P = .452, P = .379), and for new vs follow-up patients (P = .390, P = .393, Table 6 ). There was also no significant difference in anal cytology sensitivity in patients with a previous cervical HSIL/cancer vs none (53% vs 45%, P = .243 for any histological abnormality; 77% vs 67%, P = .282 for HSIL/cancer) or for a previous vaginal HSIL/cancer history vs none (52% vs 47%, P = .806 for any histological abnormality; 83% vs 70%, P = .533 for HSIL/cancer). The performance of anal cytology in women with a previous history of LGTN (excluding anal and/or perianal HSIL/cancer history) and a summary are presented in Supplementary Tables 1 and 2 , respectively.
Entering all variables that showed a significant association with the sensitivity of "any abnormality" on anal cytology to predict any abnormality on histology into a multivariable GEE logistic regression analysis, having a history of previous vulvar HSIL/cancer was no longer statistically significant (P = .097), although a positive association was nonetheless still estimated (OR, 1.69; 95% CI, 0.91-3.13). When this variable was removed from the model, immunosuppressed status (OR, 2.07; 95% CI, 1.13-3.79; P = .019) and concomitant genital HSIL/cancer (OR, 3.97; 95% CI, 1.75-9.98; P = .001) remained independent predictors of the sensitivity of cytology for detecting any abnormality in histology. Multivariable regression for the outcome of "any abnormality" on anal cytology without considering the histology results led to a final model that included positive associations with a previous history vulvar HSIL/cancer (OR, 1.71; 95% CI, 1.08-2.73; P = .023), immunosuppressed status (OR, 1.88; 95% CI, 1.17-3.03; P = .009), and concomitant genital HSIL/cancer (OR, 2.51; 95% CI, 1.47-4.29; P = .001).
DISCUSSION
Few studies have specifically analyzed the performance of anal cytology in comparison with HRA/anal histology in high-risk women. The results have been conflicting, although most studies reported a very low sensitivity [17, 23, 24] , with a small number of anal histological samples for comparison and, in most cases, a low rate of ASIL/AIN diagnosed. Information on features that might influence anal cytology has also been lacking [18] . In a study [18] with a larger number of abnormal anal samples (21% of cytology and 77% of the biopsies), a much higher sensitivity was found (70%; and for detecting anal HSIL, 84%), with a specificity of 93%. In our cohort there was a higher rate of abnormal results, including HSIL/cancer. Seventy-four percent of the women included had a previous history of anogenital HSIL/cancer, which might have influenced this rate of abnormal results and a better performance of anal cytology. The total number of biopsies was much higher in our study than in any of the previous studies, allowing us to evaluate correlations with features that might influence the performance of anal cytology. The concordance between anal cytology grades and anal histology was poor, as has been described previously [23] . Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
Overall n/n values are shown but do not correspond exactly to point estimates of indices owing to statistical correction for repeat observations. Comparison of sensitivities for immunosuppressed and nonimmunosuppressed using generalized estimating equations logistic regression: any abnormality in histology P = .002 and for high-grade histology P = .002. a Immunosuppressed patients are those with human immunodeficiency virus and/ or on drugs. The interpretation of anal cytology has been considered as a more laborious and difficult task than for the cervix [18] . Our results are in a range that is similar to that described for cervical cytology (liquid-based cytology). For the detection of cervical intraepithelial neoplasia-CIN 2+, a sensitivity ranging from 52% to 94% and a specificity ranging from 73% to 97% for "any abnormality" in cervical cytology has been reported [25] .
Immunosuppressed women were the group with the highest sensitivity (92%) of cytology for detecting anal HSIL/cancer. Previous studies, mostly including a male population (HIVpositive MSM), have also shown a better sensitivity in those who are immunosuppressed vs nonimmunosuppressed [11, 15, 16] and in those with more extensive disease [16] . In a systematic review that included studies on HIV-positive patients (mostly male), overall sensitivity of anal cytology ranged from 69% to 93% and specificity ranged from 32% to 59% [26] . As far as we know, the performance of anal cytology in women related to a previous history of and/or concomitant genital HSIL/cancer has not been described. A previous history of genital HSIL/ cancer (vs no history) was associated with a higher sensitivity of cytology for predicting anal HSIL/cancer whichever site was considered (cervix, vagina, or vulva), although these differences were not statistically significant.
The major strengths of this study relate to the size of the sample included, the largest reported in women, and the fact that a number of patient characteristics could be assessed as possible modifiers of the performance of anal cytology. All women with anal cytology also underwent HRA, and this reduced the probability of overestimation of sensitivity (if HRA was not used on those with negative cytology). All of the procedures were conducted at an institution with a substantial experience in managing these cases and by a team using the same protocol. This is relevant for obtaining better results and needs to be considered when discussing an anal screening program among high-risk populations. This also might have influenced the overall better performance of anal cytology in this study.
There are some limitations to be considered. Because of the retrospective nature of the study, there are some missing data (smoking, previous history of HSIL/cancer). Information was not recorded in some HIV-positive patients for CD4 nadir, so no analysis was done in relation to this. Several cytopathologists and pathologists interpreted the samples, which can make the results more heterogeneous due to interobserver variation. Almost all cases of concomitant genital HSIL/cancer were vulvar, so no assessment per genital site was done. Seventy-four percent of the women had a previous history of HSIL/cancer, and this may limit the generalization of these conclusions to other populations and practices. The UK reporting system for cervical cytology (and anal) is different from the Bethesda system [27] . For analysis purposes, only 4 cytological categories were used in this study (normal, low grade, high grade, and cancer), so correlations with the Bethesda system can be made: atypical squamous cells of undetermined significance and LSIL (Bethesda) with low-grade, and atypical squamous cells that [25] . HPV testing was not routinely performed with anal cytology, and there is no analysis related to the performance of HPV testing with or without anal cytology compared with HRA/histology.
In summary, the performance of anal cytology in this group of women was better than that described in most of the (few) previous studies. As with cervical cytology, anal cytology has some important limitations, including poor correlation with the histological grades, limited sensitivity, and the possibility of false-negative results [25] . Despite this, compared with HRA/ colposcopy, cytology is a less expensive method, easier to perform, and less invasive and therefore potentially suitable as a screening method in at-risk populations. A history of vulvar HSIL/cancer, immunosuppression, and concomitant genital HSIL/cancer were associated with a higher risk of abnormal anal cytology. The sensitivity for detecting anal HSIL/cancer was higher in immunosuppressed women and those with 2 or more quadrants of high-grade disease. In immunosuppressed women, given the overall performance to predict HSIL/cancer, anal cytology should be considered the initial screening technique.
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